Intas enters into exclusive licence agreement with Syna to commercialise LB-0702 in gobal markets EP News Bureau Nov 7, 2022 Syna will develop and manufacture LB-0702 and supply the product to Intas and its worldwide affiliates
Myovant Sciences and Accord Healthcare enter into exclusive licence agreement to commercialise… EP News Bureau May 13, 2022 Myovant to receive an upfront payment of $50 million, is eligible to receive commercial launch, sales-based and other milestones…
